| Beth J Alexander, PHARMD | |
|
1302 Palace Ave, Saint Paul, MN 55105-2952 | |
| (651) 699-0290 | |
| (612) 330-1757 |
| Full Name | Beth J Alexander |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacotherapy |
| Location | 1302 Palace Ave, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003134495 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P1200X | Pharmacist - Pharmacotherapy | 114937 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Beth J Alexander, PHARMD 1302 Palace Ave, Saint Paul, MN 55105-2952 Ph: (651) 699-0290 | Beth J Alexander, PHARMD 1302 Palace Ave, Saint Paul, MN 55105-2952 Ph: (651) 699-0290 |
News Archive
A new study in the February issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), shows that asthmatic and nonasthmatic African-Americans required higher doses of glucocorticoids to suppress lymphocytes, which play an important role in airway inflammation.
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.
Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Doctors at London Health Sciences Centre (LHSC) are the first in the world to use a new implantable surgical device that promises to revolutionize aortic valve bypass surgery.
Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
› Verified 4 days ago
Avni A Novotny, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2199 Highway 36 E, Saint Paul, MN 55109 Phone: 651-779-6341 Fax: 651-234-4734 | |
Mrs. Juli A Park Jankowski, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1788 Old Hudson Rd, Saint Paul, MN 55119 Phone: 651-731-9633 Fax: 651-731-9678 | |
Dr. Eddie Kit Huie, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 734 Grand Ave, Saint Paul, MN 55105 Phone: 651-227-5422 | |
Fan Zhang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 345 Smith Ave N, Saint Paul, MN 55102 Phone: 651-220-6820 | |
Dr. Justin Lee Anderson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 153 Cesar Chavez St, Saint Paul, MN 55107 Phone: 651-602-7589 | |
Jeff Ray Digre, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1440 University Ave W, Saint Paul, MN 55104 Phone: 651-646-8858 Fax: 651-646-9699 |